What is RenalSense?
RenalSense is a privately-owned entity specializing in the development of innovative medical devices for continuous, automatic monitoring of urine flow. Its flagship product, Clarity RMS, is designed to enhance patient care and optimize ICU economics by providing real-time diagnostic data. The company's strategic focus is on expanding its product line to include additional real-time parameters, thereby improving critical care management in intensive care units and peri-operative environments.
How much funding has RenalSense raised?
RenalSense has raised a total of $14M across 1 funding round:
Series A
$14M
Series A (2021): $14M with participation from BlueRed Partners
Key Investors in RenalSense
BlueRed Partners
BlueRed Partners is a Singapore-based investment fund that focuses on disruptive, early, and growth-stage technology companies from Israel, aiming to target Asian markets for its investments. By leveraging innovative technologies, BlueRed Partners seeks to foster growth and development in the region.
What's next for RenalSense?
With the recent influx of major strategic investment and a substantial total funding amount of $14M, RenalSense is poised for significant growth and product expansion. The company's trajectory suggests a move towards scaling its operations and further developing its next-generation diagnostic capabilities. This enterprise-level backing indicates strong investor confidence in RenalSense's mission to revolutionize critical care through advanced renal diagnostics, likely enabling accelerated research and development, market penetration, and strategic partnerships.
See full RenalSense company page
